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Abstract 
 
Growth arrest and DNA damage protein 34 (GADD34) is a multifunctional 
protein upregulated in response to cellular stress and is believed to mediate 
DNA repair and restore protein synthesis. In the present study we have 
examined GADD34 immunoreactivity in human myocardial tissue at defined 
survival times following cardiac arrest and determined alterations in 
expression following ischaemia. In the normal human heart, GADD34 
immunoreactivity was generally intense and present within most cells. 
GADD34 immunoreactivity was downregulated in tissue displaying ischaemic 
damage and remained intense in adjacent non-infarcted tissue. Unlike brain, 
GADD34 was not found to be upregulated in the peri-infarct zone. Cells 
displaying apoptotic changes were located in regions displaying reduced 
GADD34 immunoreactivity. In the brain, it is thought that GADD34 supports 
re-initiation of protein synthesis following ischaemia. Similarly, GADD34 may 
perform important functions in cardiac tissue in response to ischaemia.  
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GADD34 is a member of a family of genes [1] known to be upregulated in 
response to cell cycle arrest and DNA damage [2]. We, and others have 
shown that GADD34 is also upregulated in response to ischaemic stress and 
is correlated with cell survival [3, 4, 5, 6]. The carboxyl region of GADD34 
shares significant sequence homology with herpes simplex virus type 1 
protein ICP34.5. One of the functions of ICP34.5 is to preclude host cell 
protein synthesis shutdown following viral infection (Fig 1)[7]. The conserved 
region of GADD34 has been shown to compensate for the corresponding 
region in ICP34.5 in modulating protein synthesis initiation [8]. Further, 
GADD34 knockout mice display irregularities in protein synthesis regulation 
[9]. GADD34 exerts its influence on protein synthesis via the unfolded protein 
response (UPR) pathway and dephosphorylates eukaryotic translation 
initiation factor 2 (eIf2alpha) (Figure 1). GADD34 has also been shown to 
interact with other cellular proteins involved in DNA repair i.e. proliferating cell 
nuclear antigen (PCNA) [10,11]. We are currently investigating GADD34 as a 
therapeutic target for cerebral ischaemic damage. However, little is known 
about GADD34 expression in the heart and if expression is altered with 
cardiac ischaemia. This study is the first to report the presence of GADD34 in 
human myocardial tissue and to examine the consequences of ischaemia on 
its expression. 
 
 
Ethical approval for the study was granted by the local ethics committee. 
Cases of myocardial infarction were identified from post-mortem reports 
(n=30). Morphological features of infarction were identified in histologically 
stained (haematoxylin and eosin) sections and used to classify the cases into 
defined survival groups of <24hours (n=13) and 24hours-7days (n=17). Age 
matched control cases were also included (n=12) where sections displayed no 
histological evidence of recent acute infarction. GADD34 expression was 
assessed by immunohistochemistry using a rabbit polyclonal antibody for 
GADD34 (H-193, Santa Cruz, dilution 1:100). Labelling was visualised using 
the avidin-biotin complex method with diaminobenzadine as the chromogen. 
Negative controls were prepared by omitting the primary antibody. Images of 
histological sections were captured on an image analysis system (Leica 
IM500) and areas of infarction identified microscopically and mapped onto an 
outline image of the section. Images of GADD34 staining were then overlayed 
and random fields selected for scoring of GADD34 immunoreactivity. Two 
blinded investigators independently scored staining intensity within these 
fields as follows; 0= none, 1= minimal, 2= moderate and 3= maximal. Inter 
and intra investigator variability was found not to be significant. Double 
labelling of GADD34 and TUNEL (a marker of irreversible cell damage) was 
also carried out. 
 
 
Strong GADD34 immunoreactivity was evident in normal, non-infarcted 
myocardial tissue and was localised to the cytoplasm of myocytes. There was 
no alteration in the cellular localisation of GADD34 with ischaemia and all 
cases showed cytoplasmic compartmentalisation of the protein. In the <24hr 
survival group, a moderate reduction in GADD34 staining intensity was 
observed in areas of infarction with immunoreactivity remaining relatively 
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intense in adjacent non-infarcted regions although staining was slightly 
reduced in the adjacent tissue (Figure 2(a)). In contrast, in the 24hour-7day 
survival group, GADD34 immunoreactivity was markedly reduced in infarcted 
tissue compared to adjacent non-infarcted tissue and that seen in control 
cases (Figure 2 (b,c,d) (p<0.001).  Double labelling of tissue with TUNEL and 
GADD34 revealed TUNEL positive cells were present within the infarct. 
TUNEL positivity was generally associated with cells displaying a decrease in 
GADD34 immunoreactivity. Adjacent histologically non-infarcted and control 
case tissue displayed relatively few TUNEL positive cells (Figure 2(e) and (f)). 
 
 
In rodent focal ischaemia (middle cerebral artery occlusion) our group has 
shown that GADD34 immunoreactivity is significantly reduced within the 
infarct and upregulated within cells of the peri-infarct zone [4]. Recently we 
have shown GADD34 upregulation in the peri-infarct zone in human 
ischaemic stroke [6] and also in various regions of the brain following cardiac 
arrest [5]. Protein synthesis inhibition is a major event following ischaemia. It 
was once thought that protein synthesis inhibition was a beneficial 
phenomenon protecting cells from misfolded proteins via the unfolded protein 
response pathway. It is now thought that long-term inhibition of protein 
synthesis may be maladaptive and following brain ischaemia, restoration of 
protein synthesis may promote cell survival. Unlike the brain, there is doubt 
whether increased or restored protein synthesis would be beneficial in the 
heart, due to the link between increased protein synthesis and hypertrophy of 
myocytes [12, 13]. Instead, a realistic therapeutic strategy in the heart may be 
to inhibit GADD34 expression to maintain protein synthesis inhibition and 
reduce hypertrophy as work rate increases. In this study we set out to 
investigate the consequences of ischaemia on cardiac GADD34 expression. 
We report strong GADD34 immunoreactivity in the normal human heart with a 
marked decrease in immunoreactivity within infarcted tissue. However, unlike 
the situation in the brain, there was no evidence of increased GADD34 
immunoreactivity in peri-infarct zones in any of the cases examined.  
In conclusion, we have observed for the first time that GADD34 is expressed 
in myocytes of the human heart and expression is altered in response to 
ischaemia. 
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Figure 1 Schematic for the role of GADD34 in the initiation of protein 
synthesis and attenuation of programmed cell death as part of the integrated 
stress response pathway. 
 
Figure 2(a) Boxplots of GADD34 immunoreactivity scores. Scores were 
analysed using a one-way ANOVA with post-test analysis of groups. The data 
are presented using median scores as a summary measure. (***p<0.001)  
(b,c,d) Illustrations of GADD34 immunoreactivity in tissue following 24hrs-
7days survival with the boundary between light and intense GADD34 staining 
demarcating infarcted and adjacent non-infarcted tissue (b) (Scale bar= 
200μm) and at a high power showing staining in a non-infarcted (c) compared 
to that of infarcted regions (d) (Scale bar=100μm). 
(e, f) Double labelling with Tunel and GADD34 immunostaining showing no 
Tunel positive cells and intense GADD34 immunoreactivity in tissue from a 
control case (e). Tunel positive cells were limited to regions of infarct (dark 
nuclear staining) (f) and regions where GADD34 immunoreactivity was 
reduced (light cytoplasmic) (Scale bar= 50μm). 
 
 
